The U.S. Food and Drug Administration (FDA) has approved Renflexis (infliximab-abda), a biosimilar to Remicade (infliximab), making it the fourth biosimilar approved to treat inflammatory types of arthritis.
Renflexis is the second approved biosimilar to Remicade. The first one, Inflectra (infliximab-dyyb), was approved in April 2016. This is the first time the FDA has approved two biosimilars for one original, “reference” medication.
Renflexis, manufactured by Samsung Bioepis, is a TNF (tumor necrosis factor) inhibitor, also called an anti-TNF, and is given by intravenous infusion. It is approved to treat the same conditions as Remicade – rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, plaque ...more